Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCA: NOD2 genotype-guided norfloxacin prophylaxis in cirrhosis with ascites
2013-001626-26Phase 3Completed
- Sponsor
- Saarland University
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of norfloxacin in Cirrhosis, ascites and primary peritonitis, sponsored by Saarland University. Primary endpoint: 12-month overall survival. Started Sep 2013; status: completed.
02
Drugs
norfloxacin
03
Conditions
Cirrhosisascitesprimary peritonitis
Beyond the preview
Go deeper on 2013-001626-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001626-26.